A Meta-Analysis of Short-Term Outcomes of TAVR versus SAVR in Bicuspid Aortic Valve Stenosis and TAVR Results in Different Bicuspid Valve Anatomies
-
Published:2023-11-28
Issue:23
Volume:12
Page:7371
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Improta Riccardo1, Di Pietro Gianluca1, Kola Novis1, Birtolo Lucia Ilaria1, Colantonio Riccardo1, Bruno Emanuele1, Tocci Marco1, Giansante Alessandra1, Sannino Michele1, Zullino Veronica2, Monosilio Sara1, Cimino Sara1, Maestrini Viviana1ORCID, Severino Paolo1ORCID, Badagliacca Roberto1ORCID, Lavalle Carlo1, Celli Paola2, Saade Wael1ORCID, Musto Carmine3, D’Ascenzo Fabrizio4, Miraldi Fabio1, Vizza Carmine Dario1ORCID, Sardella Gennaro1, Mancone Massimo1ORCID
Affiliation:
1. Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome, 00161 Roma, Italy 2. Anesthesia and Resuscitation in Specialistic Surgeries and Transplants, Umberto I Hospital, 00161 Roma, Italy 3. San Camillo-Forlanini Hospital, 00152 Rome, Italy 4. Department of Medical Science, Division of Cardiology, Molinette Hospital, Turin University, 10126 Torino, Italy
Abstract
Background: To provide a comprehensive analysis of the current literature comparing the outcomes of surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis (BAS), with particular attention to BAV morphology in patients undergoing TAVR. Methods: Following PRISMA guidelines, all relevant articles with no design restrictions from PubMed, CCTR (Cochrane Controlled Trials Register), and Google Scholar were screened for inclusion. Studies were included if they reported clinical endpoints for SAVR and TAVR or, in BAS treated with TAVR, for type 1 and non-type 1 morphology. Odds ratio and Cohen’s D were considered as effect size measurements for qualitative and quantitative variables, respectively. Results: A total of eight studies comparing short-term outcomes between SAVR and TAVR and nine studies with outcomes data between type 1 and non-type 1 BAS treated with TAVR were considered for the final analysis. No statistically significant difference was found for what concerns the rates of death, stroke, and acute kidney injury between SAVR and TAVR. In comparison to patients undergoing SAVR, the incidence of PPI (permanent pacemaker implantation) was greater in the TAVR group (OR 0.35, 95% CI 0.15–0.79, p = 0.01), and the frequency of bleeding events was found to be higher among patients undergoing SAVR (OR 4.3, 95% CI 2.9–6.4, p < 0.001). The probabilities of 30-day mortality, stroke, and any bleeding were not significantly affected by bicuspid valve morphology in TAVR patients. PPI or development of new conduction anomalies was found to be more frequent in type 1 anatomies (OR 0.46, 95% CI 0.30–0.70, p <0.001). Mildly lower post-procedural transprothesic gradients were found in patients with type 1 morphology. Conclusions: In BAS patients, TAVR has comparable short-term outcomes rates with SAVR, but higher PPI rates and lower incidence of bleeding events. In patients undergoing TAVR, type 1 BAS is associated with lower postoperative transvalvular gradients but higher PPI rates and conduction abnormalities
|
|